Pancreas | Maryland Oncology Hematology Pancreas – Maryland Oncology Hematology

Trial ID 17160

NCT03377491
clinicaltrials.gov ID
USOR ID: 17160 Phase III
PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

Trial ID 21235

NCT04935359
clinicaltrials.gov ID
USOR ID: 21235 Phase III
A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma

Trial ID ESR 22-21698 (EIMPRIS)

NCT05438498
clinicaltrials.gov ID
Phase II/III

Trial ID

NCT04589845
clinicaltrials.gov ID
Phase II

Trial ID 22133

USOR ID: 22133 Phase II
A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (AGEN1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX)

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology